These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15208280)

  • 1. 10 best resources in...cost analysis for HIV/AIDS programmes in low and middle income countries.
    Guinness L; Levine R; Weaver M
    Health Policy Plan; 2004 Jul; 19(4):242-5. PubMed ID: 15208280
    [No Abstract]   [Full Text] [Related]  

  • 2. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS prevention more cost-effective than HAART treatment.
    AIDS Policy Law; 2002 Jun; 17(11):2. PubMed ID: 12083037
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base?
    Walker D
    Health Policy Plan; 2003 Mar; 18(1):4-17. PubMed ID: 12582104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries.
    Marseille E; Dandona L; Marshall N; Gaist P; Bautista-Arredondo S; Rollins B; Bertozzi SM; Coovadia J; Saba J; Lioznov D; Du Plessis JA; Krupitsky E; Stanley N; Over M; Peryshkina A; Kumar SG; Muyingo S; Pitter C; Lundberg M; Kahn JG
    BMC Health Serv Res; 2007 Jul; 7():108. PubMed ID: 17626616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global AIDS conference finds the issue is cash.
    Cullinan K
    Bull World Health Organ; 2002; 80(9):761-2. PubMed ID: 12378299
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south.
    Moatti JP; Spire B; Kazatchkine M
    AIDS; 2004 Jun; 18 Suppl 3():S55-61. PubMed ID: 15322486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries.
    Stover J; Bertozzi S; Gutierrez JP; Walker N; Stanecki KA; Greener R; Gouws E; Hankins C; Garnett GP; Salomon JA; Boerma JT; De Lay P; Ghys PD
    Science; 2006 Mar; 311(5766):1474-6. PubMed ID: 16456039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resource requirements to fight HIV/AIDS in Latin America and the Caribbean.
    Opuni M; Bertozzi S; Bollinger L; Gutierrez JP; Massiah E; McGreevey W; Stover J
    AIDS; 2002 Dec; 16 Suppl 3():S58-65. PubMed ID: 12685926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy where resources are limited.
    Reynolds SJ; Bartlett JG; Quinn TC; Beyrer C; Bollinger RC
    N Engl J Med; 2003 May; 348(18):1806-9. PubMed ID: 12724489
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cost of HIV treatment in highly active antiretroviral therapy in Japan].
    Kimura H
    Nihon Rinsho; 2002 Apr; 60(4):813-6. PubMed ID: 11968794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequalities in health: access to treatment for HIV/AIDS.
    Giuliano M; Vella S
    Ann Ist Super Sanita; 2007; 43(4):313-6. PubMed ID: 18209264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV prevention before HAART in sub-Saharan Africa.
    Marseille E; Hofmann PB; Kahn JG
    Lancet; 2002 May; 359(9320):1851-6. PubMed ID: 12044394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries.
    Kaufmann GR; Smith D; Bucher HC; Phanuphak P; Sendi PP; Mbidde EK; Cooper DA; Battegay M
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1303-13. PubMed ID: 12225251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts.
    Dabis F; Balestre E; Braitstein P; Miotti P; Brinkhof WG; Schneider M; Schechter M; Laurent C; Boulle A; Kabugo C; Capkun G; Seyler C; McIntyre J; Sprinz E; Bangsberg D; Van der Borght S; Egger M;
    Int J Epidemiol; 2005 Oct; 34(5):979-86. PubMed ID: 16157617
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework.
    Bautista-Arredondo S; Gadsden P; Harris JE; Bertozzi SM
    AIDS; 2008 Jul; 22 Suppl 1():S67-74. PubMed ID: 18664956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [5th French-speaking conference on HIV/AIDS (Casablanca, 28-31 March 2010)].
    Milleliri JM; Goudjo A
    Med Trop (Mars); 2010 Jun; 70(3):226-8. PubMed ID: 20734588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.